Table 3.
Unadjusted analyses
| Death < 30 days, N (%) | Death < 90 days, N (%) | Minor complication, N (%) | Major complication, N (%) | Total sample, N | |
|---|---|---|---|---|---|
| Indication | |||||
| Neurological | 36 (13%) | 60 (21%) | 25 (9%) | 47 (17%) | 281 |
| Malignancy | 20 (25%) | 41 (51%) | 10 (13%) | 7 (9%) | 80 |
| Other dysphagia | 3 (11%) | 7 (25%) | 5 (18%) | 2 (7%) | 28 |
| Operation method | |||||
| Pull | 36 (14%) | 70 (27%) | 22 (8%) | 37 (14%) | 261 |
| Introducer | 16 (17%) | 27 (28%) | 15 (16%) | 13 (14%) | 95 |
| Age | |||||
| 18–64 | 10 (9%) | 21 (18%) | 11 (10%) | 14 (12%) | 115 |
| 65–74 | 14 (13%) | 28 (25%) | 17 (15%) | 10 (9%) | 111 |
| 75 + | 35 (22%) | 59 (36%) | 12 (7%) | 32 (20%) | 163 |
| Sex | |||||
| Women | 28 (16%) | 53 (30%) | 20 (11%) | 25 (14%) | 176 |
| Men | 31 (15%) | 55 (26%) | 20 (9%) | 31 (15%) | 213 |
| Diabetes mellitus | |||||
| No | 46 (14%) | 83 (26%) | 31 (10%) | 43 (13%) | 326 |
| Yes | 13 (21%) | 25 (40%) | 9 (14%) | 13 (21%) | 63 |
| Heart failure | |||||
| No | 47 (14%) | 88 (26%) | 39 (11%) | 48 (14%) | 342 |
| Yes | 12 (26%) | 20 (43%) | 1 (2%) | 8 (17%) | 47 |
| Ischemic heart disease | |||||
| No | 41 (13%) | 77 (25%) | 32 (10%) | 43 (14%) | 309 |
| Yes | 18 (23%) | 31 (39%) | 8 (10%) | 13 (16%) | 80 |
| COPD* | |||||
| No | 55 (15%) | 98 (28%) | 37 (10%) | 50 (14%) | 356 |
| Yes | 4 (12%) | 10 (30%) | 3 (9%) | 6 (18%) | 33 |
| Body mass index (KG/M2) | |||||
| < 18.5 | 10 (15%) | 22 (33%) | 9 (13%) | 12 (18%) | 67 |
| 18.5–24.9 | 32 (16%) | 60 (30%) | 21 (10%) | 27 (13%) | 202 |
| 25.0–29.9 | 9 (15%) | 13 (22%) | 6 (10%) | 10 (17%) | 59 |
| 30 + | 1 (4%) | 3 (13%) | 0 (0%) | 4 (17%) | 23 |
| C-reactive protein (MG/L) | |||||
| < 10 | 8 (9%) | 13 (15%) | 8 (9%) | 7 (8%) | 86 |
| 10–49 | 24 (16%) | 44 (30%) | 14 (10%) | 24 (16%) | 147 |
| 50–99 | 15 (23%) | 28 (43%) | 4 (6%) | 16 (25%) | 65 |
| 100 + | 10 (32%) | 16 (52%) | 2 (7%) | 6 (19%) | 31 |
| Haemoglobin (G/L) | |||||
| < 100 | 8 (24%) | 17 (50%) | 2 (6%) | 7 (21%) | 34 |
| 100–119 | 24 (22%) | 37 (34%) | 11 (10%) | 21 (19%) | 109 |
| 120–134 | 12 (10%) | 28 (23%) | 12 (10%) | 14 (11%) | 124 |
| 135 + | 15 (18%) | 23 (28%) | 7 (9%) | 13 (16%) | 82 |
| Thrombocytes (X109/L) | |||||
| < 150 | 4 (22%) | 9 (50%) | 2 (11%) | 0 (0%) | 18 |
| 150–349 | 37 (16%) | 62 (27%) | 20 (9%) | 39 (17%) | 231 |
| 350 + | 18 (18%) | 34 (34%) | 10 (10%) | 16 (16%) | 100 |
| Creatinine (ΜMOL/L) | |||||
| < 50 | 18 (13%) | 39 (29%) | 9 (7%) | 20 (15%) | 134 |
| 50–89 | 31 (17%) | 52 (29%) | 19 (11%) | 30 (17%) | 178 |
| 90 + | 10 (33%) | 13 (43%) | 3 (10%) | 5 (17%) | 30 |
*Chronic obstructive pulmonary disease